This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna (MRNA) Beats on Q1 Earnings, Ups Vaccine Sales View
by Zacks Equity Research
Moderna (MRNA) reports first profitable quarter on the back of its success with COVID-19 vaccine. The number of COVID-19 vaccine doses delivered in the first quarter add up to 102 million.
Stock Market News for May 7, 2021
by Zacks Equity Research
Wall Street closed sharply higher on Thursday following strong labor market Data.
Will Moderna (MRNA) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Moderna (MRNA) Beats Q1 Earnings Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 39.22% and -1.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $162.84 in the latest trading session, marking a -6.19% move from the prior day.
Google, Travelzoo, Moderna, Merck and Milestone Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Google, Travelzoo, Moderna, Merck and Milestone Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
Wall Street Gears for a Hectic Earnings Week
by Zacks Equity Research
Wall Street Gears for a Hectic Earnings Week.
Will Central Banks Start to Care About Fundamentals?
by John Blank
Macro-data has been much stronger than expected.¿¿¿¿¿¿ Still, the only thing that matters is NOT whether stock traders (or pundits) take note of strong data. It is whether the Fed and other major central banks care.
Markets Up to Start Another Busy Week
by Mark Vickery
With Q1 earnings season continuing to unfold favorably (for the most part), investors look to enjoy a healthy Q2, as well.
Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are likely to focus on any updated outlook for Modena's (MRNA) authorized coronavirus vaccine and developmental progress with new COVID-19 vaccine candidate on the first-quarter earrings call.
Best Biotech Stocks & ETFs for mRNA, Gene Editing
by Neena Mishra
Here is what you should know about investing in these life changing technologies.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $175.67 in the latest trading session, marking a -1.68% move from the prior day.
Moderna (MRNA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: NVIDIA, Booking Holdings, Altria Group, Moderna and Phillips 66
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVIDIA, Booking Holdings, Altria Group, Moderna and Phillips 66
Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAD
Top Analyst Reports for NVIDIA, Booking Holdings & Altria
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Booking Holdings (BKNG), and Altria Group (MO).
Moderna (MRNA) Stock Moves -0.83%: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $168.10, marking a -0.83% move from the previous day.
Ocugen (OCGN) Up on Positive Data for COVID-19 Vaccine Candidate
by Zacks Equity Research
Ocugen (OCGN) gains as partner Bharat Biotech shared positive results of the second interim analysis of its phase III study of COVAXIN.
J&J (JNJ) Gets Usage Guidance for COVID-19 Vaccine in Europe
by Zacks Equity Research
J&J (JNJ) is set to resume shipments of its COVID-19 vaccine to European countries, following positive recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC).
Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe
by Zacks Equity Research
Emergent (EBS) halts manufacturing at Bayview facility as the FDA initiates investigation of the error that led to manufacturing of faulty doses of J&J's COVID-19 vaccine.
Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $159.87, moving -0.1% from the previous trading session.
Moderna (MRNA) Gives Pipeline Update, to Initiate New Pivotal Study
by Zacks Equity Research
Moderna (MRNA) is developing 14 mRNA-based vaccine candidates in different stages of clinical development. Interim data from ongoing cytomegalovirus and RSV vaccine studies are promising.
SMART Global, General Motors, Moderna, BioNTech and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
SMART Global, General Motors, Moderna, BioNTech and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day